Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 4/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | CTSV | O60911 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.39 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375106 | 0.79 | ACHE (0.50) | CACNA1HACHEIMPDH2CTSVCYP3A4 | |
| SCHEMBL564492 | 0.77 | IDO1 (0.67) | CACNA1HABCG2IDO1CYP19A1ESR1 | |
| SCHEMBL564482 | 0.72 | BACE1 (0.57) | CACNA1HACHEABCG2IDO1CYP19A1 | |
| SCHEMBL27013508 | 0.70 | ACHE (0.67) | CACNA1HACHECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27013475 | 0.69 | ESR1 (0.68) | CACNA1HACHECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27006405 | 0.69 | ESR1 (0.68) | CACNA1HACHECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27013445 | 0.67 | BACE1 (0.58) | CACNA1HACHEABCG2IDO1CYP19A1 | |
| Neophellamuretin SCHEMBL30766255 | 0.67 | ABCG2 (0.66) | CACNA1HACHECYP3A4CYP2D6CYP2C9 | |
| Neophellamuretin SCHEMBL27013455 | 0.67 | ABCG2 (0.66) | CACNA1HACHECYP3A4CYP2D6CYP2C9 | |
| Microfolione SCHEMBL30321441 | 0.65 | MAPT (0.66) | CACNA1HACHECYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127740-A1 | COMPOSITION CONTAINING 3-HYDROXYANTHRANILIC ACID AND COMPOUNDS THAT ALTER IRON HOMEOSTASIS AND METHOD OF ITS USE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-04-24 | — | — | US | claimed |
| US-12111313-B2 | Chelator-coated field effect transistor and devices and methods using same | Autonomous Medical Devices Inc. (US) | 2024-10-08 | — | — | US | claimed |
| US-12083105-B2 | Compositions and methods for treating adult-onset neuronal ceroid lipofuscinosis (Kufs disease) | CORNELL UNIVERSITY (US) | 2024-09-10 | — | — | US | claimed |
| WO-2023086364-A1 | COMPOSITION CONTAINING 3-HYDROXYANTHRANILIC ACID AND COMPOUNDS THAT ALTER IRON HOMEOSTASIS AND METHOD OF ITS USE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-05-19 | — | — | WO | claimed |
| US-20220031738-A1 | IRON FORMULATIONS FOR TOPICAL ADMINISTRATION AND METHODS OF TREATMENT OF IRON DEFICIENCY | DYVE BIOSCIENCES, INC. (US) | 2022-02-03 | — | — | US | claimed |
| US-20210290602-A1 | COMPOSITIONS AND METHODS FOR TREATING ADULT-ONSET NEURONAL CEROID LIPOFUSCINOSIS (KUFS DISEASE) | UNIV CORNELL (US) | 2021-09-23 | — | — | US | claimed |
| US-20210293798-A1 | Chelator-Coated Field Effect Transistor and Devices and Methods Using Same | Autonomous Medical Devices Inc. (US) | 2021-09-23 | — | — | US | claimed |
| EP-3837541-A1 | CHELATOR-COATED FIELD EFFECT TRANSISTOR AND DEVICES AND METHODS USING SAME | Autonomous Medical Devices Incorporated (US) | 2021-06-23 | — | — | EP | claimed |
| US-20210161840-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF IRON OVERLOAD | CHEVION, MORDECHAI (IL) | 2021-06-03 | — | — | US | claimed |
| EP-3781143-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF IRON OVERLOAD | Chevion, Mordechai (IL) | 2021-02-24 | — | — | EP | claimed |
| WO-2020037078-A1 | CHELATOR-COATED FIELD EFFECT TRANSISTOR AND DEVICES AND METHODS USING SAME | Sensor-Kinesis Corporation (US) | 2020-02-20 | — | — | WO | claimed |
| WO-2019202584-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF IRON OVERLOAD | CHEVION MORDECHAI (IL) | 2019-10-24 | — | — | WO | claimed |
| US-20090270495-A1 | Inhibitors of Phosphodiesterase Types 1 To 5 Based on Dioclein, Floranol, and Analogs Thereof | UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) | 2009-10-29 | — | — | US | claimed |
| EP-1877049-A2 | INCLUSION COMPOUNDS OF DIOCLEIN, FLORANOL OR ANALOGS WITH CYCLODEXTRIN AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES | Universidade Federal de Minas Gerais (BR) | 2008-01-16 | — | — | EP | claimed |
| WO-2006102728-A2 | INCLUSION COMPOUNDS OF DIOCLEIN, FLORANOL OR ANALOGS WITH CYCLODEXTRIN AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES | UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) | 2006-10-05 | — | — | WO | claimed |
| US-20250127740-A1 | COMPOSITION CONTAINING 3-HYDROXYANTHRANILIC ACID AND COMPOUNDS THAT ALTER IRON HOMEOSTASIS AND METHOD OF ITS USE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-04-24 | — | — | US | disclosed |
| US-12111313-B2 | Chelator-coated field effect transistor and devices and methods using same | Autonomous Medical Devices Inc. (US) | 2024-10-08 | — | — | US | disclosed |
| WO-2006102728-A2 | INCLUSION COMPOUNDS OF DIOCLEIN, FLORANOL OR ANALOGS WITH CYCLODEXTRIN AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES | UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006102728-A2 | INCLUSION COMPOUNDS OF DIOCLEIN, FLORANOL OR ANALOGS WITH CYCLODEXTRIN AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES | UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006102728-A2 | INCLUSION COMPOUNDS OF DIOCLEIN, FLORANOL OR ANALOGS WITH CYCLODEXTRIN AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES | UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210290602-A1 | COMPOSITIONS AND METHODS FOR TREATING ADULT-ONSET NEURONAL CEROID LIPOFUSCINOSIS (KUFS DISEASE) | CLN6, HNRNPL, HNRNPLL | CACNA1H 2518/4885ACHE 1409/4885IMPDH2 2631/4885 |
| US-12083105-B2 | Compositions and methods for treating adult-onset neuronal ceroid lipofuscinosis (Kufs disease) | CLN6, HNRNPL, HNRNPLL | CACNA1H 2518/4885ACHE 1409/4885IMPDH2 2631/4885 |
| US-20090270495-A1 | Inhibitors of Phosphodiesterase Types 1 To 5 Based on Dioclein, Floranol, and Analogs Thereof | PDE5A, PDE12, PDE2A | CACNA1H 3836/4885ACHE 804/4885IMPDH2 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.